Margarida Azevedo, MSc,  —

Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.

Articles by Margarida Azevedo

ALS Association Awards Over $1.95M to 5 Projects Advancing Research and Therapies

The ALS Association has announced the five winners of its Translational Research Advancing Therapy for ALS (TREAT ALS) grant awards, advancing research projects into improved treatments and, eventually, a cure for amyotrophic lateral sclerosis. There are two types of grants — TREAT ALS Drug Development Contract and ALS Association-Initiated — which total more…

Abnormal Proteins Found in ALS and Like Diseases Are ‘Tagged’ to Form Clumps, Study Reports

Scripps Research Institute (TSRI) scientists have identified a new player in the ribosome-associated quality control complex that “tags” abnormal proteins, prompting them to aggregate and form clumps. This study, for a first time, shows that proteins can be marked for aggregation, and may constitute a new molecular pathway underlying neurodegenerative diseases such…

ALS Research to Benefit from National Science Foundation Awards for Robotics, Online Communication

Northwestern University researchers Anne Marie Piper and Brenna Argall have received the prestigious Faculty Early Career Development (CAREER) Award from the National Science Foundation for exceptional work, some of which has implications in amyotrophic lateral sclerosis (ALS) research. The CAREER Award supports promising young faculty members who lead by example…

For Diseases Like ALS, Research by MIT and Dana-Farber Show How Financial Techniques Could Make Therapies Affordable

New research by MIT Sloan Prof. Andrew W. Lo, Dana-Farber Cancer Institute‘s David Weinstock, M.D., and Vahid Montazerhodjat, an MIT post-doctoral fellow, offers a solution for the excessive costs associated with breakthrough therapies that already exist for certain diseases such as ALS: securitized consumer healthcare loans (HCLs). The research introducing this practical…

ALS Association Announces Drug Development Contract Grant Program

The ALS Association has announced its new Translational Research Advancing Therapy for ALS (TREAT ALS) Drug Development Contract grant program, which will fund research for the development of new treatments for amyotrophic lateral sclerosis (ALS). According to a press release, the program will support research from early target identification…